Sun Pharma’s arm gets Japan MHLW approval for ILUMYA for treatment of Plaque Psoriasis

29 Jun 2020 Evaluate
Sun Pharmaceutical Industries’ one of wholly-owned subsidiaries has received approval from the Ministry of Health, Labour and Welfare (MHLW), Japan for ILUMYA (tildrakizumab) for the treatment of plaque psoriasis in adult patients who have an inadequate response to conventional therapies. Japan has approximately 430,000 people currently suffering from psoriasis.

ILUMYA is a humanized lgG1/k monoclonal antibody designed to selectively bind to the p19 subunit of IL-23 and inhibit its interaction with the IL-23 receptor, leading to inhibition of the release of proinflammatory cytokines and chemokines. 

Sun Pharma is the world's fourth largest specialty generic pharmaceutical company and India's top pharmaceutical company.

Sun Pharma Inds. Share Price

1610.85 -28.45 (-1.74%)
28-Jan-2026 15:11 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1610.85
Dr. Reddys Lab 1225.15
Cipla 1327.00
Zydus Lifesciences 895.65
Lupin 2133.50
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×